Lyxumia is used in adults who have type 2 diabetes to control their blood glucose (sugar) level. It is used together with diabetes medicines taken by mouth and/or basal insulin (long-acting insulin) in patients whose blood glucose levels are not adequately controlled by these medicines together with diet and exercise.
Lyxumia is injected once a day, in the hour before the same meal every day. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. Lyxumia is started at a dose of 10 micrograms once a day which is increased to 20 micrograms once a day after 14 days.
If the patient is already taking a sulphonylurea (another diabetes medicine) or basal insulin, the doctor may need to reduce the dose of the sulphonylurea or basal insulin because there is a risk of hypoglycaemia (low blood sugar levels). Adding Lyxumia to metformin is not associated with this risk. Lyxumia should not be given with a combination of both, basal insulin and a sulphonylurea. Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Lyxumia, lixisenatide, is a ‘GLP-1 receptor agonist’. It works by attaching to glucagon-like peptide 1 (GLP-1) receptors that are found on the surface of the cells in the pancreas and that cause the production of insulin by the pancreas. When Lyxumia is injected, lixisenatide reaches the receptors in the pancreas and activates them. This causes the release of insulin and helps to reduce blood glucose levels and control type 2 diabetes.
All pictures shown are for illustration purposes only.
Actual products may vary due to product enhancement.
Lyxumia 20 micrograms 2 pens
Description
Lyxumia is used in adults who have type 2 diabetes to control their blood glucose (sugar) level. It is used together with diabetes medicines taken by mouth and/or basal insulin (long-acting insulin) in patients whose blood glucose levels are not adequately controlled by these medicines together with diet and exercise.
Lyxumia is injected once a day, in the hour before the same meal every day. It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh. Lyxumia is started at a dose of 10 micrograms once a day which is increased to 20 micrograms once a day after 14 days.
If the patient is already taking a sulphonylurea (another diabetes medicine) or basal insulin, the doctor may need to reduce the dose of the sulphonylurea or basal insulin because there is a risk of hypoglycaemia (low blood sugar levels). Adding Lyxumia to metformin is not associated with this risk. Lyxumia should not be given with a combination of both, basal insulin and a sulphonylurea. Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively. The active substance in Lyxumia, lixisenatide, is a ‘GLP-1 receptor agonist’. It works by attaching to glucagon-like peptide 1 (GLP-1) receptors that are found on the surface of the cells in the pancreas and that cause the production of insulin by the pancreas. When Lyxumia is injected, lixisenatide reaches the receptors in the pancreas and activates them. This causes the release of insulin and helps to reduce blood glucose levels and control type 2 diabetes.
All pictures shown are for illustration purposes only.
Actual products may vary due to product enhancement.
Related Products
Ozempic 0.5mg pen Skinny pen
£160.00 Read moreLidocaine 2% 20ml bottle Korea
£15.00 Add to cartIopidine Eye drops 5mg/pt
£25.00 Read more